A phase 3 trial of DR10624
Latest Information Update: 04 Oct 2024
Price :
$35 *
At a glance
- Drugs DR 10624 (Primary)
- Indications Hypertriglyceridaemia
- Focus Registrational; Therapeutic Use
- 04 Oct 2024 New trial record
Latest Information Update: 04 Oct 2024